🚀 Join Our Team at MeMed: Head of Regulatory Affairs and Quality Assurance 🚀 At MeMed, we are revolutionizing the field of diagnostics with our cutting-edge host-response technology that differentiates bacterial from viral infections. Joining MeMed means becoming part of a dynamic and passionate team committed to making a real impact on global health. If you are a visionary leader with a deep understanding of regulatory affairs and quality assurance, we want to hear from you! 🔗 Apply now and be part of our journey to transform diagnostics and healthcare! https://lnkd.in/d6BAnUKh #Hiring #JobOpening #RegulatoryAffairs #QualityAssurance #Healthcare #Diagnostics #JoinUs #MeMed #Innovation #HealthcareTechnology
MeMed
Biotechnology Research
Haifa, Israel 14,990 followers
Decoding the Host Immune Response to Generate Insights that Improve Lives.
About us
MeMed is a leading med tech and bio-convergence company, having developed innovative diagnostic host immune response testing methods that address complex clinical dilemmas and improve patient outcomes. Our mission is to translate the complex signals of the immune system into simple diagnostic insights that transform the way we treat infectious diseases and inflammatory disorders – at the right place and the right time.
- Website
-
https://www.me-med.com/
External link for MeMed
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Haifa, Israel
- Type
- Privately Held
- Specialties
- host immune response testing, personalized diagnostics, antimicrobial resistance, systems immunology, point-of-care, IVD, med tech company, bio-convergence company, machine learning, and infectious disease testing
Locations
-
Primary
7 Nahum Heth st. Park High-Tech North
Haifa, Israel 3508506, IL
-
200 Brickstone Sq
Suite 106
Andover, Massachusetts 01810, US
Employees at MeMed
Updates
-
We're #hiring a new Head of Regulatory Affairs and Quality Assurance (RA/QA) in Haifa District. Apply today or share this post with your network.
-
"Testing and treating on the basis of gut instinct is one thing, but triaging based on a test is another." Join alejandro zuretti at ADLM 2024 for a roundtable on the MeMed BV test, which quickly differentiates between bacterial and viral infections. He will explain how this technology enhances patient care, reduces unnecessary antibiotic use, and streamlines workflows. Dr. Zuretti will share insights on the test's functionality, cost, and implementation. Learn firsthand how MeMed BV offers cost savings and improves patient experiences by reducing length of stay, increasing treatment satisfaction, and lowering morbidity and mortality, especially for children and the elderly. #HealthcareInnovation #MeMedBV #ADLM2024 #ClinicalExcellence #RapidDiagnostics https://lnkd.in/gTPaNqAW
-
🚀 We're #hiring Head of Regulatory Affairs and Quality Assurance (RA/QA)!
-
𝐅𝐫𝐨𝐦 𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐬 𝐭𝐨 𝐇𝐚𝐫𝐯𝐞𝐬𝐭𝐬: 𝐓𝐡𝐞 𝐔𝐧𝐬𝐞𝐞𝐧 𝐋𝐢𝐧𝐤 𝐀𝐟𝐟𝐞𝐜𝐭𝐢𝐧𝐠 𝐎𝐮𝐫 𝐇𝐞𝐚𝐥𝐭𝐡 𝐚𝐧𝐝 𝐅𝐨𝐨𝐝 What does a hospital setting have to do with the produce in your fridge? More than you might think. What does the produce in your fridge have to do with antimicrobial resistance? Even more. Let's dive into a startling revelation in the world of One Health. Antimicrobial resistance isn't just a clinical issue; it's a global challenge that needs a broad, collective response. The most widely used 'antibiotic'—glyphosate, known as Roundup—is primarily an agricultural herbicide. It inadvertently impacts microbial diversity and contributes to antimicrobial resistance. Surprisingly, it's used more than all medical and veterinary antibiotics combined, and often contaminates our fresh produce. This crossover shows how interconnected our actions are and the unintended consequences they can bring. As we uncover the broader impacts of glyphosate, the question arises: Are we ready to reconsider our reliance on such chemicals, especially when they could undermine our health and environmental stability? Discover more about this topic by reading our blog 👇 https://lnkd.in/dzADVKh7 #OneHealth #AntimicrobialResistance
-
-
MeMed BV has the potential to improve the diagnosis of infections, providing healthcare professionals with a reliable tool to make informed treatment decisions. In this video, Dr. Sheldon L. Kaplan explains the notable performance of MeMed BV in our recent double-blinded diagnostic accuracy study, "Apollo". Read more about our study and the findings here: https://lnkd.in/dSbgHYZT #HealthcareInnovation #DiagnosticAccuracy #MeMed #ApolloStudy #InfectionDisease #MedicalResearch
-
Here we go, we’re back with new FAQs, this week's on #suspectedsepsis in patients 🌟 ❔ Question: Can MeMed BV® be used to diagnose sepsis? ✔ Answer: Although MeMed BV is not indicated for the diagnosis of Sepsis, current guidelines emphasize the importance of promptly assessing the likelihood and cause of infection in suspected sepsis patients. MeMed BV demonstrates high accuracy in distinguishing between bacterial and viral infections in this specific patient population and may help in rapid assessment of infection etiology with a result within 15 minutes of blood draw. References: 1. Angel et al. Annals of Emergency Medicine 2023, 2. Chambliss et al. Clinical Chemistry 2023, 3. Bracken et al. Current pediatric reports 2023 *Suspected sepsis patient defined as ≥2 age-adjusted SIRS criteria (a surrogate marker for possible sepsis) https://lnkd.in/dw_T7DrY
-
We are excited to welcome Barak Hershkovitz to our team as Chief Technology Officer (CTO) and Israel Site Lead at MeMed. Barak will lead MeMed’s engineering, product operations, quality, regulatory, and clinical affairs, aiming to deliver cutting-edge products to our customers and partners worldwide. With more than 25 years of leadership experience in both startups and multinationals, Barak has guided interdisciplinary teams through the entire process of innovation—from initial concept to product development, launch, and the creation of new market segments. Barak is also a certified clinician, a graduate of the Faculty of Medicine at the Hebrew University, and is the co-author of over 30 patents. We are eager to see the directions in which his visionary leadership will steer our future initiatives. #healthcareinnovation #hostresponse
-
-
A recent article from the Journal of Emergency Medicine highlighted that a novel host-response test rapidly differentiated bacterial from a viral infection in an oncology patient with an acute respiratory illness. This improved ED resource utilization, reduced unnecessary antibiotics, and enhanced healthcare quality. Key findings showed potential reduction of: 💊 59% in unnecessary antibiotics 📃 24 % in lab testing 💉 23 % in overall costs 🏥 43% in 24h admission time #HealthcareInnovation #OncologyCare #HostResponseTest #AntibioticStewardship *The MeMed BV test has not been studied in patients with active malignancy. https://lnkd.in/dnqQi5ep
An adjunct bio-array that rapidly differentiates viral from bacterial sources can improve quality of care in Oncology patients presenting to Emergency Departments (EDs) with respiratory illnesses
jem-journal.com
-
⬆️ Revolutionize #SepsisManagement with MeMed BV! Implementing #MeMedBV could lead to significant cost savings and improved patient care by accurately identifying suspected ##sepsis cases that do not require the full protocol. Benefits Across the Board: 🚑 Emergency Departments: Faster, more accurate diagnostics. 👩⚕️ Hospitalists: Essential support for top-tier care. 🏥 Administration: Cost savings and resource efficiency. 📊 Quality Metrics: Compliance and outcome enhancements. 💊 Antibiotic Stewardship: Better antimicrobial resistance management. Imagine the impact: In an average-sized ED, MeMed BV could lead to significant cost savings and improved patient care. 🔗 Learn how to integrate MeMed BV into your sepsis protocol! https://lnkd.in/dNRdgxMe #MeMedBV #SepsisManagement
Suspected Sepsis
http://www.me-med.com